<?xml version="1.0" encoding="UTF-8"?>
<p>The generation of anti-nucleoprotein IgG/IgM and anti-RBD IgG/IgM neutralizing antibody (
 <xref rid="B95" ref-type="bibr">To et al., 2020</xref>) play an undefined role to control the infection. The transfer of these antibodies from previously infected patients to new cases (plasma convalescent administration) was initially seen as a solution for severe COVID-19 cases and has been received with enthusiasm. In March 2020, the FDA has therefore granted the clinicians the permission to access and use convalescent plasma for the treatment of life-threatening SARS-CoV-2 infection. However, there is still, limited data on the sero-conversion following the SARS-CoV-2 infection as well as on its associated side effects, such as the risk of acute lung injury (
 <xref rid="B65" ref-type="bibr">Liu et al., 2019</xref>).
</p>
